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Abstract
AIM: To evaluate the long-term treatment outcomes of 
entecavir monotherapy in treatment naive patients in 
an Australian tertiary care setting.
METHODS: A retrospective analysis of treatment naive 
patients receiving entecavir monotherapy through 
Westmead Hospital was performed. Patients were 
excluded if they had received previous treatment 
with another nucleoside or nucleotide analogue, were 
pregnant or less than 18 years old.
RESULTS: Out of 336 patients, 163 patients fulfilled 
the selection criteria. Range of follow up was 3-46 mo 
(mean 26 mo). 134 patients (82.2%) had pre-treatment 
biopsies, with 26 patients (16.0 %) demonstrating F3-4 
fibrosis. In total, 153 patients (93.9%) achieved at least 
Partial Virological Suppression (PVS), with 134 patients 
(82.2%) achieving complete virological suppression. 
The cumulative CVS and PVS rates at 36 mo were 
82.1% and 96.4%, respectively. 3 patients (1.8%) failed 
to achieve PVS, while 5 patients (3.0%) developed 
virological rebound. 128 patients (78.5%) maintained 
CVS throughout follow up. Predictors of CVS included 
lower baseline DNA level (P = 0.001), hepatitis B virus e 
antigen negative status (P = 0.001) and increasing age at 
treatment (log rank 0.001). No significant adverse effects 
were reported necessitating cessation of entecavir.
CONCLUSION: Entecavir monotherapy is efficacious 
and safe in an Australian tertiary care setting. Resistance 
and rebound rates are very low. This is similar to data 
from controlled and uncontrolled trials around the world.
© 2013 Baishideng. All rights reserved.
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INTRODUCTION
An estimated 350 to 400 million people worldwide have 
chronic hepatitis B virus (HBV) infection, a leading cause 
of  morbidity and mortality. Australia has an ethnically 
diverse population, with many migrants from the Asia-
Pacific region, where the majority of  hepatitis B related 
deaths occur[1].
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The number of  people living with chronic hepatitis 
B in Australia is estimated to be between 153  000 and 
175  000, a prevalence of  0.7% to 0.8%[2,3]. In 2010, 228 
incident cases of  hepatitis B and 6878 notifications of  
hepatitis B were reported to the Australian government’s 
National Notifiable Diseases Surveillance System[4]. This 
reflects the major burden of  disease in people with child-
hood acquired chronic hepatitis B.
In chronic HBV infection the goals of  antiviral thera-
py are to suppress HBV DNA and reduce hepatic inflam-
mation [alanine aminotransferase (ALT)], with the aim of  
preventing progression of  liver fibrosis and achieving im-
mune control [hepatitis B e antigen (HBeAg) and/or hep-
atitis B surface antigen (HBsAg) loss/conversion]. This 
reduces mortality due to cirrhosis, liver failure and HCC. 
Antiviral agents available include pegylated interferon, la-
mivudine, adefovir, entacavir, telbivudine and tenofovir.
Entecavir is an oral deoxyguanosine analog with po-
tent activity against HBV[5]. In multiple clinical trials, en-
tacavir has been found to be highly efficacious in treating 
nucleoside naive and lamividine refractory patients[6-8]. 
Emergence of  drug resistance during antiviral therapy 
is well described for HBV, particularly with lamivudine, 
with resistance appearing in 20% of  patients after 1 year 
and 70% after 5 years[9]. Entecavir has a higher genetic 
barrier to resistance than lamivudine, with quoted resis-
tance rates of  only 1%-2% in treatment naive patients af-
ter 5 years[10]. However, cross-resistance with lamivudine 
is a problem, and in patients who have failed lamivudine, 
entecavir resistance appears in up to 8% after 5 years[10,11]. 
The rates of  entecavir response and resistance in Aus-
tralia are unknown. Most published data are from large 
clinical trials, which do not necessarily reflect the rates 
seen in “real world” clinical practice. These trials were al-
most exclusively performed in the Northern Hemisphere, 
and do not reflect the unique, diverse migrant popula-
tion seen in Australia. Furthermore, much of  this data 
is based on a 1 mg dose of  entecavir, rather than 0.5 mg 
now recommended for treatment naive patients. 
The aim of  this study was to evaluate the efficacy, 
rates of  viral resistance and treatment outcomes of  
entacavir monotherapy in an Australian tertiary referral 
centre, outside of  a clinical trial environment.
MATERIALS AND METHODS
Data collection and clinical setting
Data was entered retrospectively into a database incorpo-
rating all patients receiving entecavir through the West-
mead Hospital pharmacy (Sydney, Australia) between 1 
November 2006 and 31 July 2010. 
Selection criteria
All patients receiving entecavir through the Westmead 
Hospital pharmacy were considered for analysis. Patients 
were included if  they met the following criteria: (1) 
eligible for entecavir 0.5 mg daily according to AASLD 
guidelines; (2) HBV infection for greater than 6 mo 
based on serology; and (3) deranged liver function tests 
or at least mild fibrosis on liver biopsy (> F2 on Scheuer 
classification). 
Exclusion criteria were: (1) previous treatment with 
other nucleoside analogues, nucleotide analogues or trial 
medication (except for interferon); (2) pregnancy; (3) age 
less than 18 years; (4) hepatitis delta co-infection; and (5) 
Prophylactic entecavir during immunosuppression (e.g., 
chemotherapy).
Definitions
Viral load was measured in international units/mL, using 
the Cobas Taqman assay (12 IU/mL) (Roche Diagnos-
tics, Branchburg, NJ). 
Complete and Partial Virologic Suppression were 
defined as HBV DNA < 12 IU/mL and 12-2000 IU/
mL, respectively. Virologic rebound was defined as an 
increase in viral load > 1 log10 from the previous value, in 
a patient with initial virologic suppression[12]. Cumulative 
rates of  suppression were calculated by the formula P = 
1 - (1 - n1⁄N1) (1- n2⁄N2). . .(1 - nx⁄Nx), where P is the 
cumulative probability that the event will occur, nx is the 
number of  cases at year x, and Nx is the number of  pa-
tients still followed up at year x[13]. 
The Scheuer classification system for grading and 
staging of  chronic hepatitis was used for patients that un-
derwent liver biopsy. 
Statistical analysis and ethical consideration
All statistical analyses were performed using SPSS (ver-
sion 16, Chicago IL). The study was approved by the 
Westmead Hospital Human Research Ethics Committee.
RESULTS
A total of  336 patients were included in the database, 
which collected data from 2006 to 2010. 89 patients were 
excluded due to past or current treatment with another 
agent. A further 83 patients were excluded as they 
received treatment for less than 3 mo, were less than 18 
years old, received prophylactic entecavir, had hepatitis 
delta co-infection or were pregnant. Thus, 163 patients 
were included for analysis. The patient demographics are 
summarised in Table 1.
Treatment setting
All patients were reviewed at least four-monthly by one 
of  six hepatologists at Westmead Hospital Liver Clinic, 
with assessment of  HBV DNA, viral serology, liver func-
tion tests and routine haematological and renal laboratory 
evaluation. Relevant 6-monthly HCC surveillance was 
also performed, with serum alpha-fetoprotein and he-
patic ultrasound.
The mean and median duration of  follow up were 26 
and 23 mo, respectively. The range of  follow up was 3-46 
mo, with 50% of  patients followed for greater than 24 mo. 
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Response to treatment
The response to entecavir treatment over time is detailed 
in Table 2, with a graphical summary of  virological 
suppression in Figure 1. In total, 153 patients (93.9%) 
achieved partial virological suppression (PVS), with 
134 patients (82.2%) achieving complete virological 
suppression (CVS). The cumulative CVS and PVS rates 
at 36 mo were 82.1% and 96.4%, respectively. Three 
patients (1.84%) failed to achieve partial or complete 
suppression (mean duration of  therapy 8 mo). Five 
patients (3.01%) developed virological rebound (mean 
duration of  therapy 29 mo, 3 females, 4 eAg negative, 
median fibrosis score 1 (biopsies in 4 patients), mean 
baseline DNA 9.71 × 106 IU/mL). Four of  the 5 patients 
that developed virological rebound had achieved CVS. 
Reasons for rebound included non-compliance in 4 
patients and suspected entecavir resistance in 1 patient. 
Specific viral resistance testing was not performed. Four 
patients (2.45%) were changed to another agent due to 
failed virologic suppression or virologic rebound. Of  
these, 3 patients (1.84%) were changed to tenofovir and 1 
patient (0.61%) to adefovir, with CVS and PVS achieved 
in 2 patients each, respectively. 
One hundred and twenty eight patients (78.53%) ma-
intained CVS throughout follow up. One hundred and 
twenty nine patients (79.14%) achieved PVS at 12 mo. 
The annual HBeAg positive to negative seroconversion 
rate was 14.3%. One patient (HBeAg negative) had loss 
of  surface antigen, resulting in an annual surface antigen 
loss rate of  0.3% for HBeAg negative patients and 0.2% 
for all patients, respectively.
Predictors of virological response
The time to achieve CVS was related to baseline DNA 
levels (P = 0.001) and HBeAg status at baseline (P = 
0.001) (Figure 2). 
The mean and median times to CVS were 11.4 
(9.77-13.09) and 6 (5.32-6.69) mo, respectively. For HBeAg 
negative patients the mean time was 6 mo (5.35-6.65), 
while for HBeAg positive patients it was 12 mo (3.42-20.58) 
(log rank < 0.001). 
There was a statistically significant difference in median 
time taken to achieve CVS based on age and HBeAg status 
(Table 3). There was no significant difference in loss of  
HBeAg based on age (log rank 0.559).
There was no significant effect of  duration of  therapy, 
fibrosis score or gender on time to CVS, HBeAg conversion 
or ALT normalisation. There was a trend towards faster 
ALT normalisation based on increased age (log rank 0.053). 
HCC
Among the 163 patients in the study, 4 patients (2.45%) 
developed HCC (mean time to development 19.9 
mo), while in 6 (3.68%) cases the diagnosis preceded 
commencement of  therapy. Two patients with HCC had 
a pre-treatment biopsy which did not show cirrhosis (F2 
and F3, respectively).
Treatment discontinuation and safety
Twenty one patients (12.88%) failed to follow up in clinic 
during the study period and thus did not receive ongoing 
entecavir through the hospital pharmacy. There were no 
reports of  entecavir being ceased due to adverse effects. 
DISCUSSION
This study gives an important insight into outcomes 
of  entecavir monotherapy for treatment naive patients 
with chronic hepatitis B in an Australian tertiary referral 
setting, with up to 3.5 years follow-up. To our knowledge 
it is the first study to describe the efficacy, tolerability and 
resistance rates of  entecavir in treatment naive patients 
in the Australian tertiary care setting. Daily monotherapy 
with 0.5 mg entecavir was efficacious, with 94% of  pa-
tients achieving at least partial suppression, and 82% 
achieving undetectable HBV DNA levels. Only 2% of  
patients failed to reach any significant reduction in viral 
load, while 3% developed virologic rebound. Viral resis-
tance testing was not performed. No significant adverse 
events were reported, and treatment discontinuation was 
not due to adverse events. 
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Table 1  Baseline demographics (n  = 163)  n  (%)
Age (yr)
   Mean age    52.0 (24-86)
   Mean age at start    47.4 (20-81)
Gender
   Males   113 (69.3)
   Females     50 (30.7)
Pre-treatment Biopsies   134 (82.2)
Duration of therapy (mo)
   Range   3-46
   Mean      25.63
   Median 23
   Patients > 24 mo     79 (48.5)
   Patients > 36 mo     49 (30.1)
Co-infection
   Hepatitis C       1 (0.61)
HBV DNA load (IU/mL)
   > 100  000     95 (58.3)
   2000-100  000     45 (27.6)
   12-2000     23 (14.1)
HBe antigen status     41 (25.2)
   e antigen positive   112 (68.7)
   e antigen negative   10 (6.1)
   Unknown
ALT (U/L)
   10-40     39 (23.9)
   40-400   118 (72.4)
   > 400       5 (3.01)
   Unknown       1 (0.61)
Fibrosis score  0-10 (6.13)
   135 (82.82%)   1-61 (37. 4)
 2-38 (23.3)
 3-17 (10.4)
   4-9 (5.52)
    Unknown-27 (16.6)
HBV: Hepatitis B virus; ALT: Alanine aminotransferase. 
Fahrtash-Bahin F et al . Entecavir in Australia
724 February 7, 2013|Volume 19|Issue 5|WJG|www.wjgnet.com
low baseline DNA group (10.5%). The time to achieve 
CVS was also significantly related to these factors. An 
interesting and novel finding was that the time taken to 
achieve CVS was significantly related to age. In patients 
older than 40 years old the median time to achieve CVS 
was 6 mo, whereas in patients younger than 40 years old 
it was 12 mo. This relationship was maintained following 
HBeAg status stratification, and may reflect better com-
pliance in the older population groups. 
A strength of  this study is the high proportion of  
patients in whom pre-treatment liver biopsies were per-
formed (82%). For the duration of  this study, liver biopsy 
These results are consistent with earlier registration tri-
als, which demonstrated suppression of  HBV-DNA to 
undetectable levels in 67% of  HBeAg-positive patients 
after 12 mo, and in 90% of  HBeAg-negative patients[7,8]. 
Subsequent studies confirmed durable and increasing viral 
suppression on entecavir, with undetectable HBV DNA 
achieved by 94% of  HBeAg-positive patients over 5 
years of  treatment, and in 95% of  HBeAg-negative pa-
tients over 3 years of  treatment[14,15]. Clinical trials have 
also demonstrated minimal emergence of  viral resistance 
(1.2%), after up to 6 years of  entecavir treatment[10,16]. 
Pol et al[17] analysed the efficacy and tolerability of  
entecavir in routine clinical practice settings, by comparing 
data from 5 international cohorts. In these studies CVS 
was achieved in 76%-96% of  patients, with virologic 
rebound in 0.6%-4%, and excellent overall tolerability 
and safety. Therefore the findings from our study are 
consistent with international data from other “real life” 
clinical settings, as well as earlier registration trials, which 
applied more stringent selection criteria.
As has been shown in previous studies, we found that 
the likelihood of  achieving CVS was increased in patients 
with lower baseline DNA levels and e antigen negative 
status[18,19]. Amongst patients with baseline HBV DNA 
> 108 the CVS was only 67.5% compared to 92% for pa-
tients with baseline HBV DNA < 104. This is most likely 
explained by the high proportion of  eAg positive cases 
(82%) in the high baseline DNA group compared to the 
Table 2  Follow up of DNA values and cumulative rates of complete and partial virological suppression  n  (%)
Month 0 6 12 18 24 30 36 42
Patients with DNA         163 (100)         158 (96.9)        141 (86.5)         121 (74.2)         105 (64.4)       76 (46.6)       56 (34.4)       24 (14.7)
Complete virological 
suppression
0/169 (0) 104/158 (65.8) 117/141 (83.0 )   96/121 (74.4)   94/105 (89.5) 65/76 (85.5) 46/56 (82.1) 19/24 (79.2)
Cumulative CVS 0% 66.7% 88.8% 85.1% 94.8% 93.2% 92.2% 91.6%
Partial virological 
suppression
   22/163 (13.5) 141/158 (89.2) 133/141 (94.3) 117/121 (90.7) 100/105 (95.2) 75/76 (98.7) 54/56 (96.4) 23/24 (95.8)
Cumulative PVS 13.5% 89.2% 94.9% 92.1% 96.3% 99.0% 97.3% 96.6%
CVS: Complete virological suppression; PVS: Partial virological suppression.
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was a requirement under the Australian Pharmaceutical 
Benefit Scheme to access subsidised entacavir treatment. 
Somewhat surprisingly the degree of  fibrosis was not sig-
nificantly associated with patients achieving CVS, or the 
time to achieve CVS. 
Although there was an association between DNA 
suppression and ALT normalisation, our study did not 
take into account other variables that could influence 
transaminase changes, including anthropomorphic mea-
surements, alcohol intake and intercurrent illness.
The study is limited by its retrospective analysis of  
medical records and the lack of  sufficient follow up 
data for 13% of  patients in the pharmacy registry. Fur-
thermore only a minority of  the patients included in 
the analysis (15%) had completed more than 36 mo of  
therapy. Finally, viral resistance testing was not performed 
for patients that failed to achieve PVS or had virologic 
rebound, as it was not routinely available in our clinic 
during the study period. The wide range in follow up is 
mainly due to late commencement in the study period 
with less time for follow up, drop out of  patients and 
limited treatment duration.
In conclusion, entecavir monotherapy is efficacious 
and well tolerated for the treatment of  patients with 
chronic hepatitis B infection in Australia. In our cohort 
baseline HBV DNA levels and HBeAg status influenced 
time to complete virologic suppression, consistent with 
previous studies. These factors are not independent, how-
ever, as HBeAg negative status most likely correlates with 
lower baseline HBV DNA levels. There was a very low 
incidence of  failure to suppress DNA, and no apparent 
emergence of  viral resistance on therapy. Our study sup-
ports the recommendations that 0.5 mg daily entecavir 
monotherapy is an appropriate first line agent for patients 
with treatment naive chronic hepatitis B in Australia.
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